Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 14c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of ($0.29), $0.14 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $26.97 million versus the consensus estimate of $28.42 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2022 ARCALYST revenue of $115-130 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight